CSBR:NASDAQChampions Oncology, Inc. Analysis

Champions Oncology is trading at $5.79, which sits below its 20‑day, 50‑day and 200‑day moving averages, signaling a bearish technical backdrop. The RSI of 44 suggests modest momentum, while the MACD line has just crossed above its signal, offering a faint bullish hint. However, the stock exhibits a 48% 30‑day volatility and a low beta of 0.66, indicating price swings that are not closely tied to the broader market. The discounted cash‑flow model pins a fair value near $4.71, well under the current price, yet the forward PE of 57.9 and a price‑to‑book of 18.8 imply the market is pricing in strong growth expectations that may be stretched.
Fundamentally, the company posted a 2.8% YoY revenue decline to $57.9M, negative operating margins, and a trailing EPS of –$0.18, while carrying $5.0M of debt against $7.1M of cash, yielding a high debt‑to‑equity ratio. Recent news highlights a mixed Q3 performance—record core study revenue but a 3% revenue dip—while management remains optimistic about achieving year‑over‑year revenue growth and positive adjusted EBITDA. The combination of cash‑burn, regulatory exposure, and limited liquidity underscores a cautious outlook.